Aprea Therapeutics stockholders elect director slate, ratify auditor, approve say-on-pay at 2025 annual meeting

Aprea Therapeutics, Inc.

All three Class III directors (Jean-Pierre Bizzari, Oren Gilad, John B. Henneman III) elected with >95% of votes cast for.
Ratification of EisnerAmper LLP as 2025 auditor passed with 2,916,782 for, 49,535 against, 35,669 abstain.
Non-binding advisory vote on exec compensation approved (1,628,716 for, 58,828 against, 34,829 abstain).
Say-on-frequency vote: 1 year received 1,159,068 votes; plurality for 1-year frequency.
Quorum achieved with 3,817,718 shares (69% of shares entitled to vote) represented.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.